Company / Revenue
AXIM BIOTECHNOLOGIES, INC. Revenue History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$39.5K
FY2023
5-year range
$8.9K / $195.6K
FY2019-FY2023
Trend
+345.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue changed +345% YoY in FY2023, a notable deviation from the 8-year average annual change of +116%.
Based on SEC 10-K filings.
$39,518 in FY2023 with a 10-year CAGR of -6.2%.
Declined from $195,614 to $39,518 over the past 5 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -27.4%
- 10-Year CAGR
- -6.2%
Key checks
Key Insights
- 5-year CAGR of -27.4%, indicating a declining trend.
- In FY2023, revenue increased 345.3% year-over-year.
- Peak revenue was recorded in FY2018.
- Lowest revenue in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $39.5K | +345.3% |
| FY2022 | $8.9K | -95.5% |
| FY2018 | $195.6K | +311.2% |
| FY2017 | $47.6K | +1.1% |
| FY2016 | $47.1K | -4.2% |
| FY2015 | $49.1K | -34.5% |
| FY2013 | $75.0K | +73.1% |
| FY2012 | $43.3K | +333.3% |
| FY2011 | $10.0K | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026